The treatment of advanced renal cell cancer with high-dose oral thalidomide

British Journal of Cancer

Volumn 85, Issue 7, 2001, Pages 953-958

  Stebbing, J ^a   Benson, C ^a   Eisen, T ^a   Pyle, L ^a   Smalley, K ^a   Bridle, H ^b   Mak, I ^c   Sapunar, F ^a   Ahern, R ^a   Gore, M E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Renal cell carcinoma; Thalidomide

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 6; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CYTOKINE PRODUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; LETHARGY; MALE; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CONSTIPATION; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; SLEEP STAGES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 17944362585     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6692025     Document Type: Article

References (37)

1. Results of a randomised clinical trial comparing SC interleukin-2, SC alpha-2A-interferon and iv bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients
2. Prurigo nodularis and photosensitivity and AIDS: Treatment with thalidomide
3. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxantheone-4-acetic acid
4. Thalidomide is an inhibitor of angiogenesis
5. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
6. Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+ and CD8+ renal-cell carcinoma-infiltrating lymphocytes
7. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
8. Tumour angiogenesis: Therapeutic implications
9. Clinical applications of research on angiogenesis
10. Antiangiogenic activity of prostate-specific antigen
11. Neuropathy after intake of thalidomide (Distaval)
12. Anticytokine approaches to the treatment of anorexia and cachexia
13. Thalidomide for the treatment of oral apthous ulcers in patients with human immunodeficiency virus infection
14. Interleukin-6 and renal cell cancer: Production, regulation and growth effects
15. The differential expression of proinflammatory cytokines IL-6, IL-8 and TNF-alpha in renal cell carcinoma
16. The thalidomide analogue CC-3052 inhibits HIV-l and tumour necrosis factor-alpha expression in acutely and chronically infected cells in vitro
17. Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
18. Interferon-α and survival in metastatic renal carcinoma: Early results of a randomised controlled trial
19. Update on the pathogenesis and treatment of Kaposi's sarcoma
20. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung carcinoma
21. Endostatin: An endogenous inhibitor of angiogenesis and tumour growth
22. Thalidomide - A revival story
23. Reciprocal paracrine interactions between tumour cells and endothelial cells: The angiogenic progression' hypothesis
24. Inflammatory bowel disease management. Some thoughts on future drug developments
25. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
26. New life in a sleeper: Thalidomide and Crohn's disease
27. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals
28. Antitumour activity of thalidomide in refractory multiple myeloma
29. Hypothesis: Thalidomide embryopathy-proposed mechanism of action
30. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages
31. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
32. Potentiation of cytotoxic cancer therapies by TNP-40 alone and with other anti-angiogenic agents
33. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma
34. Expression of adhesion receptors on rat limb bud cells and results of treatment with a thalidomide derivative
35. Thalidomide for the treatment of chronic graft-versus-host disease
36. Rapid cytokine release in cancer patients treated with interleukin-2
37. Evidence that tumour necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumour nude mice